On July 10, Alebund Pharmaceuticals-B (09637.HK) fell 5.26% in regular trading, trading at HK$28.48/share, with turnover of HK$6.41 million. The decline marks a second consecutive session of selling pressure following the stock's 12.89% surge on July 8.

The stock has been experiencing sharp volatility since its IPO on June 29 at a price of HK$22.6 per share. After soaring over 103% on its first trading day, the stock entered a pattern of rapid rallies and pullbacks. A July 8 spike was driven by disclosure that GIC Private Limited and LAV Asset Management collectively acquired over 1.32 million shares on listing day, investing approximately HK$58.72 million combined, with GIC's stake rising to 7.09% and LAV's to 7.20%. The subsequent two-day retreat suggests short-term traders are locking in gains accumulated during the institutional-buying-driven rally.

The company is a biopharmaceutical firm focused on kidney diseases. Its core product AP301, an oral phosphate binder for hyperphosphatemia, has completed China Phase III registration trials and is expected to submit an NDA imminently, with commercialization projected within 12 to 24 months.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)